Dan Troy joined GSK as Senior Vice President & General Counsel in September 2008. Reporting to Andrew Witty, he is based in Franklin Plaza, Philadelphia PA, and is a member of the Corporate Executive Team.
Previously a Partner at the Washington law firm Sidley Austin LLP, where he represented mainly pharmaceutical companies and trade associations on matters related to the US Food and Drug Administration (FDA) and government regulations, Dan was formerly Chief Counsel for the FDA, where he served as a primary liaison to the White House and the US Department of Health and Human Services (HHS).
While leading an office of attorneys who reviewed and approved all major regulations and guidances, Dan oversaw the legislative implications of many of the most important issues facing the pharmaceutical industry today, including the reform of the Hatch-Waxman Act and subsequent legislative ratification. His office also approved and managed all agency litigation, and Dan established procedures for the FDA legal team to follow in preparing and then litigating high-profile cases.
Dan is a graduate from Cornell University’s School of Industrial and Labor Relations, and earned his law degree from Columbia University School of Law, where he was a member of the Law Review and a Kent Scholar. After graduation from law school, he was a law clerk for the US Circuit Court of Appeals for the District of Columbia Circuit.
*****
A person listed as a contributor has spoken or otherwise participated in Federalist Society events, publications, or multimedia presentations. A person's appearance on this list does not imply any other endorsement or relationship between the person and the Federalist Society. In most cases, the biographical information on a person's "contributor" page is provided directly by the person, and the Federalist Society does not edit or otherwise endorse that information. The Federalist Society takes no position on particular legal or public policy issues. All expressions of opinion by a contributor are those of the contributor.
The Pharmaceutical Industry: Intellectual Property and Pricing
Boston College Student Chapter
Boston College Law School885 Centre St
Newton Centre, MA 02459
Are MDLs working? An Assessment of Centralization
Multidistrict Litigation (MDL) Conference
Kirkland & Ellis LLP1450 G Street, NW
Washington, DC 20005
Intellectual Property and the Free Market: Is Pharmaceutical Marketing Regulation Economically Helpful or Hurtful?
Georgetown Law, Gewirz, 12th FloorLitigation: The Future of Federal Pre-Emption
2009 National Lawyers Convention
The Mayflower Hotel1127 Connecticut Avenue, NW
Washington, DC 20036
Federal Preemption and the Supreme Court
Administrative Law Practice Group and American Enterprise Institute
American Enterprise Institute1150 Seventeenth Street, N.W.
Washington, DC 20036
Are MDLs working? An Assessment of Centralization
Multidistrict Litigation (MDL) Conference
Multidistrict litigation (“MDL”) accounts for nearly half of all civil cases in federal courts. Although...
Are MDLs working? An Assessment of Centralization
Multidistrict Litigation (MDL) Conference
Multidistrict litigation (“MDL”) accounts for nearly half of all civil cases in federal courts. Although...
Litigation: The Future of Federal Pre-Emption
2009 National Lawyers Convention
Pre-emption issues are a perennial area of concern for the U.S. Supreme Court. Significant cases...
Litigation: The Future of Federal Pre-Emption
2009 National Lawyers Convention
Pre-emption issues are a perennial area of concern for the U.S. Supreme Court. Significant cases...
Federal Preemption at the Supreme Court
It has been a striking time for federal preemption at the Supreme Court. Last term,...